Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

The goal of this clinical trial is to learn about Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure MSS(microsatellite stability) metastatic colorectal cancer. The main question it aims to answer is: The efficacy and safety of Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the third line and beyond treatment of MSS metastatic colorectal cancer. Participants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on meta

Trial Details

NCT ID

NCT06613113

Phase

NA

Sponsor

Ningbo Medical Center Lihuili Hospital

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Fruquintinib

Locations (sample)

• Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

• Age ≥ 18 years old, gender not limited；
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1；
• Previously identified as MSS type mCRC；
• Metastatic colorectal cancer (mCRC) with disease progression after receiving standard second-line treatment according to Chinese Society of Clinica…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →